Bimosiamose disodium (TBC-1269Z) is used as an anti-inflammatory agent by inhibiting neutrophil recruitment to sites of inflammation through blockade of the initial rolling phase; it shows therapeutic potential in ischemia-reperfusion injury, significantly improving survival rates, reducing liver enzyme levels, ameliorating neutrophil migration, and alleviating histologic damage in animal models.